X

Ranbaxy Laboratories Ltd.- (Amalgamation) Stock Analysis

Large Cap
Evaluated by 2831 users | BSE: 500359 | NSE: RANBAXY |
Pharmaceuticals & Drugs
Ranbaxy Laboratories, is India's largest pharmaceutical company incorporated in 1961. The company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries.  Ranbaxy has world-class manufacturing facilities in 11...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Mar'14
Return on Capital Employed 21.47%6.81%10.31%5.15%3.5%4.4%10.74%-0.89%6.29%-2.57%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 3,7203,5654,0304,1364,4704,7805,6707,7996,3045,492
Y-o-Y Gr. Rt.--4.2%13%2.6%8.1%6.9%18.6%37.6%-19.2%-12.9%
Adjusted EPS (Rs.) 14.245.0311.276.243.187.1320.62-6.614.74-10.63
Y-o-Y Gr. Rt.--64.7%124.1%-44.6%-49%124.2%189.2%-132.1%NA-324.3%
Book Value per Share (Rs.) 67.2463.6262.7867.7584.0894.03121.6345.3244.9320.33
Adjusted Net Profit 529187420233134300868-279201-451
Net Op. Cash Flow (Rs. Cr.) 411107315686-390-6651,169128662-974
Debt to Cash Flow from Ops 0.339.610.085.11-9.49-5.033.6533.757.26-5.08
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Ranbaxy Laboratories Ltd.- (Amalgamation) should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 4.4%4.2%-1.1%-12.9%
Adjusted EPS -196.8%-227.3%-180.2%-324.3%
Book Value per Share -12.5-24.7-44.9-54.8
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Mar'14
Return on Equity (%) 21.917.6717.769.524.277.6418.74-7.910.43-37.32
Operating Profit Margin (%) 17.926.1515.619.285.7213.622.1117.739.52-1.87
Net Profit Margin (%) 14.235.2610.425.622.996.2715.31-3.573.18-8.21
Debt to Equity 0.050.431.361.391.050.850.832.272.535.75
Working Capital Days 222221205222238281296299411375
Cash Conversion Cycle 779810511610110593107175107
Corporate Governance What do we look at?
Corporate Governance
Board Credentials
Promoter's holding
Transparency
Integrity
Entity Percentage Holding
Promoters 63.22%
Institutions 21.16%
Non-Institutions 15.61%
Others 0.01%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Ranbaxy Laboratories, is India's largest pharmaceutical company incorporated in 1961. The company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries.  Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Ranbaxy has its R & D centre that helps company to have long term competitive

Ranbaxy Laboratories, is India's largest pharmaceutical company incorporated in 1961. The company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries.  Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Ranbaxy has its R & D centre that helps company to have long term competitive advantage. It caters treatment to segment of diseases that includes Cardiovascular, Central Nervous System, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology.

Ranbaxy's top 20 products, ranging from Anti-infectives to Dermatological, account for revenues of over $600 Million. Using the finest R&D and Manufacturing facilities, that manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, Active Pharmaceuticals and intermediates (API).

In 2001 Ranbaxy entered consumer healthcare through launch of 4 brands Revital, Pepfiz, Gesdyp & Garlic Pearls.

In 2004 launched its first herbal range of products through New Age Herbals (NAH), with products offering remedies in categories of Cough & Cold (Olesan Oil & Cough Syrups) and Appetite Stimulant (Eat Ease).

In 2005, another popular brand, Chericof - The complete cough formula was introduced. During 2006, the business registered sales of $19 Million registering a growth of 19%. Revital, the flagship brand continues to maintain leadership in its segment.

It also produces molecules like Simvastatin, Ciprofloxacin, Amoxycillin, Isotretinon and many more

In April 2014 Sun Pharmaceutical Industries Ltd and Ranbaxy Laboratories Ltd announced that they have entered into definitive agreements pursuant to which Sun Pharma will acquire 100% of Ranbaxy in an all-stock transaction. Under these agreements, Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. This exchange ratio represents an implied value of Rs 457 for each Ranbaxy share, a premium of 18% to Ranbaxy’s 30-day volume-weighted average share price and a premium of 24.3% to Ranbaxy’s 60-day volume-weighted average share price, in each case, as of the close of business on April 4, 2014.

Milestone achieved

• 2013 -Ranbaxy wins the ASSOCHAM Innovation Excellence Platinum Award for SynriamTM, a new age cure for malaria

• 2012 - Ranbaxy wins the 2012 Frost & Sullivan Malaysia Excellence Award for being adjudged the Malaysian Pharmaceutical Company of the Year in the Generics Drug Category

•2012 Launch India's first New Chemical Entity (NCE), SynriamTM, a new age cure for Malaria

• 2011  Launch Atorvastatin, a generic version of the world’s largest selling cholesterol lowering drug, in the US with 180-day market exclusivity

• 2011 - Ranbaxy is felicitated with the New Jersey Business and Industry Association Award for Excellence in the Business Expansion Category

• 2010 - Ranbaxy enters the Golden jublee year

• 2010- For the first time Ranbaxy delivered quarterly sales of over $500 million

• 2010  Launch First-to-File (FTF) product Donepezil hydrochloride tablets 5 mg and 10 mg with 180-day market exclusivity in the US Healthcare System

• 2009- Dailchi Sankyo and Ranbaxy announced reconstitution of Ranbaxy executive leadership. Ranbaxy was acquired by Daiichi Sankyo through acquisition of it 52.5% of the equity share capital.

• 2008- Ranbaxy partnered with Daiichi Sankyo Company to create a strategic combination of an innovator and generic powerhouse

• 2007- Ranbaxy has signed new R&D agreement with GSK

• 2006-Ranbaxy acquires generic unbranded business of GSK in Italy & Spain

• 2006 -Ranbaxy acquires Terapia largest independent generic pharma company in Romania for $ 324 million

• 2003 Ranbaxy receives The Economic Times award for corporate excellence for ‘The Company of the year’2002-03

• 2000 Ranbaxy acquires Bayers generic business in Germany. It has alliance with Glaxo SmithKline for Drug discovery & clinical development

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback